A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

Conditions

Diseases of the Digestive System - Pancreas | Diseases of the Endocrine System

Phase I-II

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to determine the safety and efficacy of NI-03.

Ages
18 years - 85 years
Gender
Both

Find out more about who can participate in this trial

Trial with
Stason Pharmaceuticals, Inc.
Start Date
03/01/2020
End Date
07/31/2018

For more information about this study, contact:

Christina Rose

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Thiruvengadam Muniraj, MD, FRCP
Assistant Professor of Medicine (Digestive Diseases); Associate Chief for Endoscopy, Digestive Health, Yale New Haven Health System; Director, Yale Center for Pancreatitis; Director, Bariatric Endoscopy, Internal Medicine

Sub-Investigators

Last Updated
07/15/2021
Study HIC
#2000023420

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information